Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

It’s a bigger deal than any deal announced in 2024 ... the dealmaking environment from a regulatory perspective." Novo Nordisk’s global head of business development and M&A, John MacDonald ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

The CEO of <strong>Novo Nordisk</strong> warned of the impact of tariffs on the pharmaceutical industry. Weight-loss drugs, including Ozempic and Wegovy, could cost ...

or more than 30, which is classified as obesity. In its federal budget submission, Novo Nordisk said 6.3 million Australians were living with obesity. The Australian Institute of Health and ...

From 'back burner' to full throttle Novo Nordisk's rare disease ambitions first began to shift when Lars Fruergaard Jørgensen donned the mantle of CEO in 2017. “One of the intuitions that Lars ...

Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks, but shares fell, likely ...

That’s a big thing. It takes a little time, but I think it should be great for us." Shares in electric vehicle maker Tesla (TSLA) dropped more than 15% on Monday, with the stock a further 3% in the ...